Acute Respiratory Distress Syndrome Market Size (7MM) was ~USD 1,643 million in 2023 and It is expected to increase at a CAGR of 3.6%, estimates DelveInsight

DelveInsight's "Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU4, and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Unlock key insights into the Acute Respiratory Distress Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Acute Respiratory Distress Syndrome Market Size- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acute Respiratory Distress Syndrome Market Report
• On 28 October 2025, PPD Development LP conducted a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments.
• The total Acute Respiratory Distress Syndrome incidence in the United States were around 591 thousand cases in 2023.
• The United States contributed to the largest incident population of Acute Respiratory Distress Syndrome, acquiring ~62% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 34% and 4% of the total population share, respectively, in 2023.
• Among the EU4 countries, Germany accounted for the largest Acute Respiratory Distress Syndrome incidence (181 thousand Cases) cases followed by France (47 thousand Cases), whereas Spain accounted for the lowest number of cases (25 thousand Cases) in 2023.
• In 2023, it was estimated that there were around 177 thousand Incident cases were of Mild severity, 276 thousand cases of Moderate severity, and 138 thousand cases of Severe severity in the US.
• According to DelveInsight estimates, in 2023, among the risk factor-associated cases of ARDS in the US, there are approximately 210,560 incident cases of pneumonia, 175,076 cases of sepsis, 18,169 cases of trauma, 61,157 cases of aspiration, 8,974 cases of pancreatitis, 4,757 cases of COVID-19, 63,242 cases of other types, and about 49,340 cases of unknown types.
• The leading Acute Respiratory Distress Syndrome Companies such as MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.
• Promising Acute Respiratory Distress Syndrome Therapies such as EB05 (NI 0101), Lucinactant (sinapultide), ExoFlo (DB-001), BIO-11006, Alteplase (Actilyse), and many others.

Stay ahead in the competitive landscape of the Acute Respiratory Distress Syndrome Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Acute Respiratory Distress Syndrome Treatment Market- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Respiratory Distress Syndrome Epidemiology Segmentation in the 7MM
• Total Acute Respiratory Distress Syndrome Incident Cases
• Acute Respiratory Distress Syndrome Severity-specific Incident Cases
• Acute Respiratory Distress Syndrome Incident Cases by Risk Factors

Download the report to understand which factors are driving Acute Respiratory Distress Syndrome epidemiology trends @ Acute Respiratory Distress Syndrome Prevalence- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Respiratory Distress Syndrome Emerging Drugs
• Sabizabulin (Veru-111): Veru
Sabizabulin (VERU-111) is an orally bioavailable bis-indole that binds to the colchicine binding site of alpha and beta tubulin and inhibits tubulin polymerization at low nanomolar concentrations. The drug disrupts the microtubules, the central mechanism that contributes to both their antiviral and anti-inflammatory activities, by disrupting the intracellular transport of viruses, such as SARS CoV-2, along microtubules. Microtubule trafficking is critical for viruses to cause infection. The company is currently investigating a Phase III study of VERU-111 for the treatment of SARS-CoV-2 in patients at high risk for ARDS. However, a planned interim analysis was conducted in the first 150 patients randomized into the study.

• xoFlo (DB-001): Direct Biologics
ExoFlo (DB-001) by Direct Biologics is an extracellular signal product isolated from human Bone Marrow Mesenchymal Stem or Stromal Cells (BM-MSCs) that contains growth factors and extracellular vesicles, including exosomes. ExoFlo provides natural bioactive signals that downregulate inflammation, direct cellular communication, and upregulate tissue repair in humans. These vesicles are 30-150 nm in size and are purified using proprietary cGMP processing. Recently, in July 2022, the company initiated the evaluation of the drug in Phase III for COVID-19 moderate-to-severe ARDS. In April 2022, the US FDA awarded ExoFlo a Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of ARDS associated with COVID-19.

Acute Respiratory Distress Syndrome Market Outlook
ARDS, a life-threatening condition, was described as a form of respiratory failure that closely resembled respiratory distress syndrome in infants. This can be caused by a variety of pulmonary (such as pneumonia and aspiration) or non-pulmonary (like sepsis, pancreatitis, and trauma) abuses, leading to the development of non-hydrostatic pulmonary edema. ARDS is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue.

Discover the future of Acute Respiratory Distress Syndrome Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Acute Respiratory Distress Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Respiratory Distress Syndrome Companies
MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.

Scope of the Acute Respiratory Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Acute Respiratory Distress Syndrome Companies- MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.
• Acute Respiratory Distress Syndrome Therapies- EB05 (NI 0101), Lucinactant (sinapultide), ExoFlo (DB-001), BIO-11006, Alteplase (Actilyse), and many others.
• Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome Current marketed and Acute Respiratory Distress Syndrome Emerging Therapies
• Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome Market drivers and Acute Respiratory Distress Syndrome Market Barriers

Explore the dynamics of the Acute Respiratory Distress Syndrome Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Acute Respiratory Distress Syndrome Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Acute Respiratory Distress Syndrome Market Report Introduction
3. Acute Respiratory Distress Syndrome (ARDS) Market Overview at a Glance
4. Methodology of ARDS Epidemiology and Market
5. Acute Respiratory Distress Syndrome Executive Summary
6. Key Events
7. Acute Respiratory Distress Syndrome Market Disease Background and Overview
8. Acute Respiratory Distress Syndrome Patient Journey
9. Acute Respiratory Distress Syndrome Epidemiology and Patient Population
10. Acute Respiratory Distress Syndrome Emerging Drug Profiles
11. Acute Respiratory Distress Syndrome Market Analysis
12. Key Opinion Leaders' Views
13. SWOT Analysis
14. Acute Respiratory Distress Syndrome Unmet Needs
15. Acute Respiratory Distress Syndrome Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.